Sign up to save your podcasts
Or
Share The FDA Expands Indication for Baloxavir Marboxil to Include Post-Exposure Influenza Prevention
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The FDA Expands Indication for Baloxavir Marboxil to Include Post-Exposure Influenza Prevention
Host: Linda Bernstein, Pharm.D.
To prevent the flu from spreading concurrently with COVID-19, The U.S. Food and Drug Administration has expanded the approved indication for baloxavir marboxil to include post-exposure prevention of influenza. On this episode of The Drug Report, Dr. Linda Bernstein dives into this oral anti-influenza drug.
Published December 2, 2020
View all episodes
By ReachMDHost: Linda Bernstein, Pharm.D.
To prevent the flu from spreading concurrently with COVID-19, The U.S. Food and Drug Administration has expanded the approved indication for baloxavir marboxil to include post-exposure prevention of influenza. On this episode of The Drug Report, Dr. Linda Bernstein dives into this oral anti-influenza drug.
Published December 2, 2020